- MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing
Merck KGaA, Darmstadt, Germany today announced positive top-line results from a Phase II study of sonelokinab (M1095), an investigational anti-IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F.
You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.
If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website.
By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.